Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)

Autor: Charlotte Strandhave, Christian Daugaard Peters, Kent L. Christensen, Krista Dybtved Kjaergaard, Bo Martin Bibby, Ida Noerager Tietze, Bente Jespersen, Marija Kristina Novosel, Jens Dam Jensen

Publikováno v: Peters, C D, Kjaergaard, K D, Jensen, J D, Christensen, K L, Strandhave, C, Tietze, I N, Novosel, M K, Bibby, B M & Jespersen, B 2015, ' Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics : A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study) ', PLOS ONE, vol. 10, no. 6 . https://doi.org/10.1371/journal.pone.0126882
Peters, C D, Kjaergaard, K D, Jensen, J D, Christensen, K L, Strandhave, C, Tietze, I N, Novosel, M K, Bibby, B M & Jespersen, B 2015, ' Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics : A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study) ', PLOS ONE, vol. 10, no. 6, pp. e0126882 . https://doi.org/10.1371/journal.pone.0126882
PLoS ONE, Vol 10, Iss 6, p e0126882 (2015)
PLoS ONE

BACKGROUND AND AIM: Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan.DESIGN: Randomized, double-blind, placebo-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::035dbadf850cc441cd13e91210d4f9bb
https://doi.org/10.1371/journal.pone.0126882